Favorable clinical heart and bone effects of anti-thyroid drug therapy in endogenous subclinical hyperthyroidism

Journal of Endocrinological Investigation

Volumn 30, Issue 3, 2007, Pages 230-235

  Buscemi, S ^a,c   Verga, S ^a   Cottone, S ^a   Andronico, G ^a   D'Orio, L ^b   Mannino, V ^b   Panzavecchia, D ^b   Vitale, F ^b   Cerasola, G ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b Partinico Hospital   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

Author keywords

Bone; Heart; Methimazole; Subclinical hyperthyroidism; Therapy

Indexed keywords

ANTITHYROID AGENT; LIOTHYRONINE; THIAMAZOLE; THYROTROPIN; THYROXINE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BONE STRENGTH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; ECHOGRAPHY; FEMALE; HEART ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEEL; HOLTER MONITORING; HUMAN; HYPERTHYROIDISM; LIOTHYRONINE BLOOD LEVEL; MALE; OSTEOPOROSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SUBCLINICAL HYPERTHYROIDISM; SUPRAVENTRICULAR PREMATURE BEAT; SYSTOLIC BLOOD PRESSURE; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; ULTRASOUND;

EID: 34250638653     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03347430     Document Type: Article

References (31)

1. Helfand M. Screening for subclinical thyroid dysfunction in nonpregnant adults: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2004, 140: 128-41.
2. Toft AD. Subclinical hyperthyroidism. N Engl J Med 2001, 345: 512-6.
3. Kalmijn S, Mehta KM, Pols HA, Hofman A, Drexhage HA, Breteler MM. Subclinical hyperthyroidism and the risk of dementia. The Rotterdam study. Clin Endocrinol 2000, 53: 733-7.
4. Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 2001, 358: 861-5.
5. Vanderpump MPJ, Tunbridge WMG, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol 1995, 43: 55-68.
6. Helfand M, Redfern CC. Clinical guideline, part 2. Screening for thyroid disease: an update. American College of Physicians. Ann Intern Med 1998, 129: 144-58.
7. AACE Thyroid Task Force. American association of clinical endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract 2002, 8: 458-67.
8. Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease. Scientific review and guidelines for diagnosis and management. JAMA 2004, 291: 228-38.
9. Brunn J, Block U, Ruf G, Bos I, Kunze WP, Scriba PC. Volumetric analysis of thyroid lobes by real-time ultrasound. Deutsche Medizinische Wochenschrift 1981, 106: 1338-40.
10. Greenspan SL, Bouxsein ML, Melton ME, et al. Precision and discriminatory ability of calcaneal bone assessment technologies. J Bone Miner Res 1997, 12: 1303-13.
11. Hans D, Dargent-Molina P, Schott AM, et al. Ultrasonographic heel measurements to predict hip fracture in elderly women: the EPIDOS prospective study. Lancet 1996, 348: 511-4.
12. Riggs BL, Melton LJ 3rd. Involutional osteoporosis. N Engl J Med 1986, 314: 1676-86.
13. Lee WY, Oh KW, Rhee EJ, et al. Relationship between subclinical thyroid dysfunction and femoral neck bone mineral density in women. Arch Med Res 2006, 37: 511-6.
14. Mudde AH, Houben AJ, Nieuwenhuijzen Kruseman AC. Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism. Clin Endocrinol (Oxf) 1994, 41: 421-4.
15. Kisakol G, Kaya A, Gonen S, Tunc R. Bone and calcium metabolism in subclinical autoimmune hyperthyroidism and hypothyroidism. Endocr J 2003, 50: 657-61.
16. Gurlek A, Gedik O. Effect of endogenous subclinical hyperthyroidism on bone metabolism and bone mineral density in premenopausal women. Thyroid 1999, 9: 539-43.
17. Yonem O, Dökmetas HS, Aslan SM, Erselcan T. Is antithyroid treatment really relevant for young patients with subclinical hyperthyroidism? Endocr J 2002, 49: 307-14.
18. Britto JM, Fenton AJ, Holloway WR, Nicolson GC. Osteoclast mediate thyroid hormone stimulation of osteoclastic bone resorption. Endocrinology 1994, 134: 169-76.
19. Eriksen EF. Normal and pathological remodeling of human trabecular bone: three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease. Endocr Rev 1986, 7: 379-408.
20. Inoue M, Tawata M, Yokomori N, Endo T, Onaya T. Expression of thyrotropin receptor on clonal osteoblast-like rat osteosarcoma cells. Thyroid 1998, 8: 1059-64.
21. Kumeda Y, Inaba M, Tahara H, et al. Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism. J Clin Endocrinol Metab 2000, 85: 4157-61.
22. Bauer DC, Ettinger B, Nevitt MC, Stone KL. Risk of fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med 2001, 134: 561-8.
23. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994, 331: 1249-52.
24. Auer J, Scheibner P, Mische T, Langsteger W, Eber O, Eber B. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. Am Heart J 2001, 142: 838-42.
25. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001, 344: 501-9.
26. Sgarbi JA, Villača FG, Garbeline B, Villar HE, Romaldini JH. The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism in clinical and heart abnormalities. J Clin Endocrinol Metab 2003, 88: 1672-7.
27. Biondi B, Palmieri EA, Fazio S, et al. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J Clin Endocrinol Metab 2000, 85: 4701-5.
28. Polikar R, Burger AG, Scherrer U, Nicod P. The thyroid and the heart. Circulation 1993, 87: 1435-41.
29. Klein I, Hong C. Effects of thyroid hormone on cardiac size and myosin content of the heterotopically transplanted rat heart. J Clin Invest 1986, 77: 1694-8.
30. Col NF, Surks MI, Daniels GH. Subclinical thyroid disease. Clinical applications. JAMA 2004, 291: 239-43.
31. Faber J, Wiinberg N, Schifter S, Mehlsen J. Haemodynamic changes following treatment of subclinical and overt hyperthyroidism. Eur J Endocrinol 2001, 145; 391-6.